(Q52892865)

9 May 2018

meta-analysis

0 references

title

The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. (English)

1 reference

9 May 2018

author

Kim Brosen

series ordinal

3

1 reference

9 May 2018

Peter C. Gøtzsche

series ordinal

2

object named as

P C Gøtzsche

1 reference

9 May 2018

P M Christensen

1

1 reference

9 May 2018

publication date

1 January 1997

1 reference

9 May 2018

European Journal of Clinical Pharmacology

published in

1 reference

9 May 2018

volume

51

1 reference

9 May 2018

issue

5

1 reference

9 May 2018

page(s)

389-393

1 reference

9 May 2018

https://scigraph.springernature.com/pub.10.1007/s002280050219

exact match

0 references

cites work

Mortality in relation to smoking: 40 years' observations on male British doctors

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

The Causes of Cancer: Quantitative Estimates of Avoidable Risks of Cancer in the United States Today

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Lung cancer and the debrisoquine metabolic phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Debrisoquine metabolism and genetic predisposition to lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Urinary factors of kidney stone formation in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Debrisoquine oxidation phenotype and susceptibility to lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Comparison of normal and asthmatic circadian rhythms in peak expiratory flow rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Statistical problems in the reporting of clinical trials. A survey of three medical journals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Meta-analyses of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Meta-analysis: State-of-the-Science

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Polymorphic oxidation of debrisoquine in lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Metabolic oxidation phenotypes as markers for susceptibility to lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Clinical significance of the sparteine/debrisoquine oxidation polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Debrisoquin oxidation genotype and susceptibility to lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Preliminary analysis of the Concorde trial. Concorde Coordinating Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002280050219

CYP2D6 genotyping and the association with lung cancer susceptibility

21 January 2018

1 reference

12 December 2020

Dextromethorphan oxidation phenotypes as markers for susceptibility to lung cancer

1 reference

12 December 2020

The effect of tobacco on lung cancer risk depends on CYP2D6 activity.

1 reference

12 December 2020

Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6.

1 reference

12 December 2020

Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.

1 reference

12 December 2020

Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients

1 reference

12 December 2020

Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls

1 reference

12 December 2020

Methodological issues in the interpretation of studies of the CYP2D6 genotype in relation to lung cancer risk

1 reference

12 December 2020

PCR-based CYP2D6 genotyping for Finnish lung cancer patients

1 reference

12 December 2020

Debrisoquine metabolism and lung cancer risk

1 reference

12 December 2020

The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today

1 reference

12 December 2020

Polymorphism of human CYP2D genes involved in drug metabolism: possible relationship to individual cancer risk.

1 reference

12 December 2020

The pharmacogenetics of chemical carcinogenesis

1 reference

12 December 2020

Identifiers

DOI

10.1007/S002280050219

1 reference

9 May 2018

1 reference

9 May 2018